Laboratory research paves the way for a clinical trial to see if an FDA-approved drug used to prevent organ transplant rejection can work against these aggressive brain tumors.
Demsky joined the University of Michigan Rogel Cancer Center communications team in 2019. Prior to that he served as director of communications for the University of Michigan's Life Sciences Institute and science editor for Medicine at Michigan Magazine.
Researchers Optimistic After Dose-Determining Trial of Compound Against Metastatic Castration-Resistant Prostate Cancer
The multi-institution phase 1b/2a clinical trial found good tolerability and encouraging efficacy data for the pan-BET bromodomain inhibitor in combination with enzalutamide.
Multi-institution analysis identifies a new chromosomal abnormality linked to enzalutamide resistance.
While heat shock protein 90 inhibitors have shown limited benefit in directly treating cancer, low doses may improve the efficacy of radiotherapy, a new study finds.
Rather than attacking cancer cells directly, new cell-model research probes weaknesses in pancreatic cancer’s interactions with other cells to obtain nutrients needed for tumor growth.
In cell and mouse models, miR181a showed promise as a biomarker for early stage ovarian cancer and may help make immunotherapy treatment more effective.